REG - Sareum Holdings PLC - Director’s Dealing

Sareum HoldingsAnnouncement

27/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250327:nRSa3635Ca&default-theme=true

RNS Number : 3635C  Sareum Holdings PLC  27 March 2025

Sareum Holdings PLC

("Sareum" or the "Company")

Director's Dealing

Cambridge, UK, 27 March 2025 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, announces that Dr Stephen
Parker, Executive Chairman, purchased 84,033 ordinary shares of 1.25 pence
each in the capital of the Company ("Ordinary Shares") at an average price of
11.9 pence per share on 26 March 2025.

In addition, persons connected with Dr Parker are interested in a
further 25,680 Ordinary Shares in the Company, over which Ordinary Shares Dr
Parker has voting rights discretion.

Therefore, following the transaction, Dr Parker has direct and indirect
interests in an aggregate 405,045 Ordinary Shares in the Company, representing
approximately 0.30 per cent. of the Company's currently issued share capital.

The notification below, which has been made in accordance with the
requirements of the Market Abuse Regulation, provides further details.

PDMR Notification Form:

 1           Details of the person discharging managerial responsibilities/person closely
             associated

 a)          Name                            Stephen Parker
 2           Reason for the notification
 a)          Position/status                 Executive Chairman
 b)          Initial notification/amendment  Initial notification
 3           Details of the issuer, emission allowance market participant, auction
             platform, auctioneer or auction monitor
 a)          Name                            Sareum Holdings plc
 b)          LEI                             213800PKERN2DY8FFM72
 4           Details of the transaction(s): section to be repeated for (i) each type of
             instrument; (ii) each type of transaction; (iii) each date; and (iv) each
             place where transactions have been conducted
 a)          Description of the financial instrument, type of instrument     Ordinary shares of 1.25 pence each in the share capital of Sareum Holdings plc

             Identification code                                             GB00B02RFS12

 b)          Nature of the transaction                                       Purchase of shares
 c)          Price(s) and volume(s)
                                                                                                   Price(s)              Volume(s)
                                                                                                   £0.119                84,033
 d)          Aggregated information

             -      Aggregated volume                                        84,033 Ordinary Shares

             -      Weighted Average Price                                   11.9 pence per Ordinary Share

 e)          Date of the transaction                                         26 March 2025
 f)          Place of the transaction                                        London Stock Exchange (AIM)

 

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No.
596/2014, which is part of UK law by virtue of the European Union (Withdrawal)
Act 2018.

- ENDS-

For further information, please contact:

 Sareum Holdings plc

 Stephen Parker, Executive Chairman         01223 497700

                                            ir@sareum.co.uk
 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                020 7409 3494

 Oberon Capital (Joint Broker)

 Mike Seabrook / Nick Lovering              020 3179 5300

 Hybridan LLP (Joint Broker)

 Claire Noyce                               020 3764 2341

 ICR Healthcare (Financial PR)

 Jessica Hodgson / Davide Salvi             020 3709 5700

 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, with a planned
initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

The Company has recently acquired the license for SRA737, a clinical-stage
Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA
damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about:blank)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHMZGZFVVVGKZM